If you tell someone you eat Apricot Seeds every day, chances are you’ll get a raised eyebrow—or maybe even a stern warning: “Be careful—those have cyanide in them!” This phrase has echoed through media headlines, government rulings, and medical offices for decades. It has fueled fear, controversy, and even criminal prosecutions. But what if we’ve been told only half the story? What if Apricot Seeds, and the compound within them known as Vitamin B17, were never the poison they were painted to be—but rather one of nature’s most overlooked tools in the fight against cancer?
At the heart of the controversy lies a natural compound called amygdalin, also known as Vitamin B17. Found in the kernels of apricots, bitter almonds, and over 1,200 other fruits and plants, amygdalin breaks down in the digestive process into glucose, benzaldehyde, and cyanide. That last word—cyanide—is the lightning rod. To the public, “cyanide” conjures images of poison capsules and crime dramas. What’s rarely explained is that the cyanide in B17 is not free-floating and destructive. It is bound within the amygdalin molecule. Nature designed it with a safety lock.
The “key” that unlocks it is an enzyme called beta-glucosidase—an enzyme found in much higher concentrations around cancer cells than around healthy cells. When amygdalin meets cancer cells, the key turns, the bond breaks, and the cell is destroyed. Meanwhile, healthy cells are protected by another enzyme, rhodanese, which neutralizes any cyanide release, converting it into harmless byproducts. In this way, B17 functions like a smart weapon: targeting cancer cells while sparing normal ones.
This mechanism has been detailed in G. Edward Griffin’s book World Without Cancer: The Story of Vitamin B17. Yet outside natural health circles, the distinction between bound cyanide and free cyanide has been lost—or deliberately obscured. In the 1970s, Dr. John A. Richardson, MD, administered Laetrile (a purified form of amygdalin) to cancer patients at his San Francisco clinic. Many of these patients were considered beyond hope, having exhausted conventional treatments. What he witnessed was extraordinary: some of the sickest began to recover strength, shrink tumors, and regain quality of life.
But regulators saw something else. The FDA launched raids. Vials of Laetrile were confiscated. Dr. Richardson and his staff were arrested—not for harming patients, but for daring to give them a choice outside of government-approved treatments. The message was clear: this wasn’t about science. It was about control. They weren’t silencing quackery. They were silencing a story of hope.
Critics insist there is “no credible evidence” that B17 or Laetrile works. Yet, a closer look at the scientific record reveals a more complex story. Griffin’s book outlines the metabolic theory of cancer, suggesting it is a deficiency disease akin to scurvy or pellagra, arising when a vital nutrient (B17) is absent from the diet. Reintroducing the nutrient, he argues, could restore the body’s natural defense against rogue cells.
The persistent fear narrative, many argue, lies in economics. Cancer is a multi-billion-dollar industry, sustained by surgery, radiation, chemotherapy, and patented drugs. A natural substance like B17 cannot be patented. You cannot own the rights to an Apricot Seed. And where there is no patent, there is no incentive for investment. Instead of exploring B17’s potential, the system invested in burying it. Articles warned of “toxic seeds.” Regulators banned distribution. Medical boards threatened physicians who experimented.
The real danger wasn’t that Apricot Seeds would kill patients. It was that they might kill the Golden Goose of endless profits. Today, the debate over B17 continues. Patients are demanding alternatives. Communities are rediscovering that healing can come from God-given resources, not just patented pills. The question isn’t only: Does B17 work? The question is: Shouldn’t patients have the right to decide for themselves?
This is a Guest Post from our friends over at WLTReport.
